FuGENE® has continued to innovate and now offers a full portfolio of best-in-class transfection reagents that span applications across DNA, RNA and CRISPR/Cas9 delivery, into a wide range of biologically relevant cell lines. We seek to meet the needs of researchers, scientists, and clinicians in delivering nucleic acids and proteins to cells at market-leading efficiencies while remaining gentle on cells.
FuGENE® knows how important the high efficiency and gentle DNA transfection of your cells is to your research & production. For 25 years we have led the way with our broad-spectrum DNA transfection reagents. Whether it’s for life science research, the production of antibodies, proteins, viruses, or for groundbreaking therapeutic needs, FuGENE® has you covered with our innovative transfection reagents.
FuGENE® 4K is our newest and most advanced, 100% synthetic, multi-component transfection reagent designed for the delivery of DNA into both challenging and routine mammalian cell lines. FuGENE® 4K was developed to improve upon our widely published and trusted FuGENE® HD reagent. Leveraging our gentle and highly efficient proprietary transfection chemistry, FuGENE® 4K provides efficient and safe entry of DNA into a wide range of cells. This mechanism allows users to obtain higher performance than other competitor reagents including Lipofectamine® 3000.
FuGENE® 4K reagent outperforms Lipofectamine® 3000. A549, C2C12, HCT116, CHO-K1, HeLa, NIH3T3, LNCaP, PANC1 & SKOV3 cell lines were seeded in 96-well plates according to user guides and subsequently transfected with FuGENE® 4K or Lipofectamine® 3000 (registered trademark of Thermo Fisher Scientific) and a GFP expressing plasmid at the following transfection reagent to DNA ratios (3:1, 4:1 & 5:1). Cells were then analyzed via flow cytometry 48 hours post-transfection to measure % GFP expressing cells and % total cell viability (via propidium iodide dye). The graphs above show the superior performance of FuGENE® 4K vs. Lipofectamine® 3000.
FuGENE® HD is a 100% synthetic, multi-component, non-liposomal transfection reagent designed for the delivery of DNA into more challenging eukaryotic and insect cell lines. FuGENE® HD interacts with nucleic acids to provide efficient and safe entry into the cell, thus allowing users to overcome barriers in difficult-to-transfect lines such as primary cells, stem cells, and suspension cells. Its simple, easy-to-use protocol allows users to free up valuable lab time.
COS-7 Cell Line Transfected with FuGENE® HD & GFP Plasmid
HEK293 Cell Line Transfected with FuGENE® HD (X-Gal Stain)
HEK-293T Viral Production Cell Line Transfected with FuGENE® HD & RFP Plasmid
HCT116 Cells were seeded in 96-well plates according to user guides and subsequently transfected with FuGENE® HD or Lipofectamine® 3000 (registered trademark of Life Technologies Corporation)+ GFP expressing plasmid at recommended 3:1 ratios. Cells were then analyzed via flow cytometry at 24, 48, and 72 hours post-transfection to measure +GFP expressing cells and total cell viability (propidium iodide). Graphs above show the superior performance of FuGENE® HD vs. Lipofectamine® 3000 in HCT116 cells.
A549, COS7, HCT116, HEK293, and HeLa cells were seeded in 96-well plates according to users guide and subsequently transfected with FuGENE® HD Reagent & GFP expressing plasmid at various FuGENE® HD to Total DNA ratios. Cells were then analyzed after 24 hours for transfection efficiency utilizing flow cytometry. Data for normalized GFP expression is plotted in the graph to left highlighting the best FuGENE® HD to DNA ratio for each cell line tested.
FuGENE® 6 is a multi-component lipid-based transfection reagent that allows for the efficient delivery of all sizes of DNA into a broad range of cell types with extremely low cytotoxicity. FuGENE® 6 saves time and resources because it minimizes reagent preparation, media changes, and optimization. It also eliminates the side effects of toxicity while providing high transfection efficiency, which leads to successful transfection of more than 800 cell lines. FuGENE® 6 can be used for the study of gene expression, cancer biology, cell-based protein & virus production, and for many other applications in functional genomics, proteomics, and cellular analysis.
A549, COS7, HCT116, HEK293, and HeLa cells were seeded in 96-well plates according to users guide and subsequently transfected with FuGENE® 6 Reagent & GFP expressing plasmid at various FuGENE® 6 to Total DNA ratios. Cells were then analyzed after 24 hours for transfection efficiency utilizing flow cytometry. Data for normalized GFP expression is plotted in graph shown on the right highlighting the best FuGENE® 6 to DNA ratio for each cell line tested.
Our customers requested it and that’s why we’ve leveraged the FuGENE® technology to bring you our newest reagent, FuGENE® SI. FuGENE® SI allows our customers to obtain the highest siRNA knockdown efficiency combined with extremely low cell toxicity in eukaryotic cells.
Save time, Save money, Save reagents.
Harnessing the same gentle reliability as our market-leading DNA Transfection Reagents, we are proud to introduce to you: FuGENE® SI: our innovative RNA Transfection reagent engineered for the delivery of siRNAs into all eukaryotic cell lines. FuGENE® SI is a 100% synthetic, non-toxic, multi-component transfection reagent designed for high-efficiency delivery of RNA molecules into eukaryotic cell lines. FuGENE® SI allows researchers to obtain maximum efficiency knockdowns while being more gentle on cells than competitor’s reagents. Request a sample today for all your RNAi delivery needs, and See the Unseen™ with FuGENE® SI.
Human MDA-MB-468 (breast cancer) cells were reverse transfected in 6-well plates with 40 pmol of indicated targeting siRNA and negative/positive controls (Silencer Select®, Life Technologies) with either 7.5ul of FuGENE® SI or 7.5ul of RNAimax® (Life Technologies) per well. 72 hours after transfection the cells were collected and analyzed via western blot for expression of target genes STAT3 and CEBPB. Results demonstrates that FuGENE SI yields robust knockdown of target genes and performs better or comparable to RNAiMax®.
Human MCF-7 cells plated in 6-well microplates were transfected with 10, 20, or 30nM of ARID4B targeting siRNA or negative control (Millipore Sigma, Mission®) utilizing 7.5ul of FuGENE SI per well. 48 hours hours after transfection the cells were collected and 20ug of total cell lysate was analyzed via western blot for expression of target gene ARID4B and control gene HSP70. Results demonstrate that FuGENE® SI enables robust knockdown of endogenously expressed ARID4B in biologically relevant human cancer cell lines with no unintended off-target effects.
HEK293-GFP & NIH3T3-GFP Cell lines (Cell Biolabs®) were seeded in 96-well plates according to user guides and subsequently transfected with 0.2, 1.0, or 5 pmols of GFP targeting siRNA or negative control (Horizon Discovery/Dharmacon®), along with 0.3ul of Transfection Reagent FuGENE® SI or 0.3ul of Lipofectamine® RNAiMax (Life Technologies Corporation). Cells were then analyzed via flow cytometry 48 hours post-transfection to measure % knockdown of GFP & total cell viability. Graphs above show the superior knockdown performance of FuGENE® SI vs. Lipofectamine® RNAiMax in HEK293 and NIH3T3 cells.
HEK293-GFP & NIH3T3-GFP Cell lines (Cell Biolabs®) were seeded in 96-well plates according to user guides and subsequently transfected with 0.2, 1.0 or 5 pmols of GFP targeting siRNA or negative control (Horizon Discovery/Dharmacon®), along with 0.3ul of Transfection Reagent FuGENE® SI. Cells were then analyzed via flow cytometry 48 hours post-transfection to measure total cell viability. Graphs above show the gentle and non-toxic transfection of siRNAs with FuGENE® SI
From research applications to product development, you can count on our FuGENE® team to provide customizable and specialized solutions to meet your institution’s goals. Whether it’s an entirely new reagent, a custom fill volume, or outsourcing a complete workflow, you can entrust our experts to deliver success.
